SARRC’s research program brings together scientists, research methods, and stakeholders to gain a better understanding of possible causes of autism, identify better treatments, and educate others about how to improve the quality of life for those impacted by ASD and their families.
Current studies and pharmaceutical trials with openings
Aging & Autism Study
In partnership with Barrow Neurological Institute (BNI), SARRC is studying the aging process of individuals with ASD. SARRC is recruiting participants with a diagnosis of ASD and without ASD including men and women ages 26-70 and 18-70 years old. Participants are asked to complete an evaluation at SARRC and then undergo an FMRI scan at BNI. During the scan, participants will complete tasks related to memory and thinking. For more information, contact 602.218.8184.
Autism and Mindfulness Intervention
Adults with ASD often experience depression and anxiety symptoms which can affect quality of life. Participants will attend 8 weekly sessions involving stress-reduction education and social support that have reduced depression in adults with ASD. Our research aims to understand brain functioning before and after stress-reduction classes to help us better understand how symptom improvements relate to brain functioning in adults with ASD. This study is open to all adults, ages 18 and older, with autism. To learn more about this study or to enroll, contact the Autism Brain Aging Lab at 480.727.3970.
Early Childhood Learning Study
Early experiences last! SARRC is studying how early learning experiences impact children with and without autism. If you have a preschool-age child, you can help us develop preschool programs where all children, with and without autism, can play and learn together. By participating in this study with your child, you can learn more about your child’s cognitive, language, and social development, which can help you understand how best to support your child’s learning! *Your child does not need to be enrolled in preschool to participate. Learn more by contacting a member of our research team at 602.606.9888.
LAPS Study (Long-term Antipsychotic Pediatric Safety)
Is your child taking Risperdal or Abilify? Would you like your child to be closely monitored for side effects of these medicines? If so, the LAPS study might be a good fit for your family! SARRC is working with The Pediatric Trials Network (PTN), to find the safest and most effective doses of commonly used medicines for infants and children. Children aren’t just little adults. Their bodies are growing and changing, meaning that they process medicines differently than adults do. To learn more about the LAPS study, contact us at 602.218.8183.
The Naturalistic Observational Diagnostic Assessment (NODA) is the product of a SARRC Research collaboration with Behavior Imaging. NODA is an app that allows families to seek and receive an autism diagnosis from the comfort of their home by submitting video evidence of their child’s behavior to a team of diagnostic clinicians. SARRC and Behavior Imaging are continuing to do research on this tool. En Espanol: Dignostico del autismo – obtenga respuestas rapidamente. For more information, contact 602.340.8717, Ext. 2000. *Tambien en espanol.
ADHD Study (CAPSTONE)
ADHD can make it difficult for some to stay focused and on task. While there are treatment options available for ADHD symptoms, these treatments can be ineffective, resulting in unwanted side effects, or become difficult to stop using. As a result, the CAPSTONE research study is being conducted at SARRC to explore additional adult ADHD treatment options. SARRC is evaluating an oral investigational drug to see if it helps treat symptoms in adults with ADHD. For more information, contact 602.606.9888.
The Rocket Study
SARRC is working with Ovid Therapeutics to recruit for the Rocket study, a clinical research study on Fragile X syndrome (FXS). The study is open to males ages 13 to 22 and is focused on an investigational compound that may be effective in treating some of the behavioral symptoms associated with FXS. Travel reimbursement is available. For more information, contact 602.218.8183 or click here.
The CONNECT- Fragile X syndrome (FXS) study, sponsored by Zynerba, is evaluating the efficacy of cannabidiol gel for children and adolescents with FXS ages 3 to 17. This investigational compound is the first and only pharmaceutically-produced cannabidiol, also called CBD, formulated as a gel for transdermal delivery. SARRC is one of 20 participating sites in the United States, Australia and New Zealand. Travel reimbursement is available for participating families. For more information, contact 602.218.8183 or click here.
The Janssen Study is investigating the efficacy of an investigational medication targeting the most common behavioral symptoms of autism. We are enrolling adolescents and young adults with ASD ages 13 through 30 to participate. Participants must have a study partner (e.g. parent, caregiver, significant other) available to attend all appointments. For more information, contact 602.218.8183.
SARRC has partnered with Roche Pharmaceuticals for many years – currently, we are collaborating on the Aviation Study, a pediatric clinical trial for autism. This trial is investigating a new compound to observe its potential effects on the social communication and interaction skills of children with autism, ages 5-17. For more information, contact 602.218.8183.
This study is sponsored by Roche, and is investigating novel technology that may provide a more accurate, objective measure of social functioning in participants with autism ages 5 to 45. There is no medication involved in this trial. Participants will use state-of-the-art technology both at our center during study visits, and in their home. For more information, contact 602.218.8183.
Adults with autism see, hear and feel the world in a unique way. We don’t want to change this. But sometimes, adults with autism may find certain situations challenging. SARRC is a clinical trial site for Roche Pharmaceuticals, which is examining an investigational drug to assess whether it can help adults with ASD better manage certain social and communication challenges. To learn if the investigational drug works, we are recruiting participants to join the V1ADUCT clinical trial. Participants must be at least 18 years old, diagnosed with ASD, and have someone they see and speak to regularly who is willing and able to be their ‘study partner.’ For more information, contact 602.218.8183.
SPARK for Autism
The Simons Foundation Autism Research Initiative is offering SPARK—an online, long-term study of genetics and autism. SPARK will collect and analyze genetic samples (saliva) from all participants to help autism researchers learn about genetic and non-genetic causes of autism. SPARK is open to all individuals with a professional diagnosis of autism, as well as their parents. Participation can take place either in your home via mail-in kit or at SARRC. For more information, contact 602.340.8717, Ext. 8175.